iRadimed Chief Financial Officer Sold $135K In Company Stock

On December 3, a recent SEC filing unveiled that John Glenn, Chief Financial Officer at iRadimed IRMD made an insider sell.

What Happened: Glenn's recent move involves selling 2,500 shares of iRadimed. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value is $135,449.

iRadimed's shares are actively trading at $53.84, experiencing a down of 0.0% during Tuesday's morning session.

All You Need to Know About iRadimed

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.

Financial Insights: iRadimed

Positive Revenue Trend: Examining iRadimed's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.04% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Key Insights into Profitability Metrics:

• Gross Margin: With a high gross margin of 77.44%, the company demonstrates effective cost control and strong profitability relative to its peers.

• Earnings per Share (EPS): iRadimed's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.4.

Debt Management: iRadimed's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Market Valuation:

• Price to Earnings (P/E) Ratio: iRadimed's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 36.87.

• Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.63, iRadimed's stock is perceived as being overvalued in the market, particularly in relation to sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): At 28.48, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Delving Into the Significance of Insider Transactions

Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.

Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.

Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.

Cracking Transaction Codes

Navigating through the landscape of transactions, investors often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of iRadimed's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.